# RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

> **NCT06797531** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 177 (estimated)

## Conditions studied

- HR+/HER2- Early Breast Cancer

## Interventions

- **DRUG:** ribociclib

## Key facts

- **NCT ID:** NCT06797531
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797531, "RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06797531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*